Skip to content

Definition of a standard length of nasogastric feeding tube in adults: randomized clinical trial

Definition of a standard length of nasogastric tube in adults: randomized clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-7vr7xs
Enrollment
Unknown
Registered
2015-02-26
Start date
2014-01-06
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia, Aspiration

Interventions

A pilot study was conducted with 30 patients to calculate the sample. Experimental group: 10 patients received EXU measure (distance obtained between the points: the earlobe + xiphisternum + midpoint
Procedure/surgery

Sponsors

Hospital das Clínicas da Unicamp
Lead Sponsor
Faculdade de Enfermagem - Universidade Estadual de Campinas
Collaborator

Eligibility

Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Adult patients; with aged over 18 years; of both sexes; with medical prescription of nasogastric feeding tube.

Exclusion criteria

Exclusion criteria: Are excluded from the study patients with prescribed nasogastric tube for drainage, with mechanical obstruction of the Digestive System and morphological abnormalities of the gastrointestinal tract, with prior gastric surgery, morbidly obese, with diseases that may alter the external abdominal anthropometric measures. It will be considered an absolute contraindication for the introduction of nasogastric tube, patients who experience recent nasal surgery, coagulation disorders, esophageal varices, cauterization or recent ligation of esophageal varices, alkaline intake.

Design outcomes

Primary

MeasureTime frame
Presentation of the expected outcome: The expected outcome is to validate one of the three measures for introduction of nasogastric feeding tube in adults with safety deposit of food in the stomach of the patient. The nasogastric tube of measure that will have a higher incidence frequency in the patient's stomach body will be clinically validated in adult patients. Presentation of the method used to check the expected outcome: To estimate the sample size was used chi-square test. The estimate of this parameter required the calculation were obtained from a pilot study had 30 patients. Analysis by the radiologist - Validation of the measure of a nasogastric tube in adults assessed by radiological examination. There was only one radiologist responsible for performing the reading radiological images and issue the final report. This radiologist was blinded in relation to the method used to insert the probe in the patient. In each radiograph was scanned each of the four sites in the distal tip of the probe: probe distal esophagus; the distal tip of the probe in the gastroesophageal junction; the distal tip of the probe into the stomach; distal points of the probe in pylorus or duodenum. If the distal tip of the probe was located in the stomach, the responsible radiologist examined the two regions of the stomach: fundus of the stomach and stomach body. Analysis of the data by statistical - The acquired data and manually recorded by the researcher during data collection were entered into a spreadsheet program Microsoft Excel for Windows version 2007 (Microsoft Inc.). Then the database was transported to the SAS 9.2 software for analysis, with the support of statistical responsible for the study. The description of quantitative variables was determined by calculating the position and dispersion measures. For categorical variables was calculated frequency and percentages. The chi-square test was used to compare the groups in relation to outcome variable (position of the dista

Secondary

MeasureTime frame
Does not apply.

Countries

Brazil

Contacts

Public ContactMaria Isabel;Sandra Cristina de Freitas;de Oliveira Santos

Faculdade de Enfermagem - Universidade Estadual de Campinas;Faculdade de Enfermagem - Universidade Estadual de Campinas

beloca4@yahoo.com.br;sancrisvos@gmail.com55(19)3521-8820;55(19)3521-8820

Outcome results

None listed

Source: REBEC (via WHO ICTRP)